Treatment-Free Survival Over 6 Years of Follow-up in Patients With Metastatic Non-small Cell Lung Cancer Treated With First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in CheckMate 227 Part 1

INTRODUCTION: Treatment-free survival (TFS) characterizes periods of disease control and durable clinical benefit following treatment discontinuation in patients treated with immunotherapy. In CheckMate 227 Part 1, nivolumab plus ipilimumab showed long-term durable overall survival (OS) benefit versus chemotherapy in patients with metastatic NSCLC. Here, we report updated long-term TFS results. METHODS: This analysis included all randomized patients (tumor PD-L1 expression

• Peters, S.
• Regan, M. M.
• Paz-Ares, L. G.
• Reck, M.
• Borghaei, H.
• O'Byrne, K. J.
• Brahmer, J. R.
• Penrod, J. R.
• Li, J.
• Tracy, L.
• Yuan, Y.
• Bushong, J.
• Lee, A.
• Eccles, L. J.
• Ray, S.
• Ramalingam, S. S.